In the late autumn of 2025, the Moscow EXPO CENTRE exhibition center brought together the wisdom and innovation of the global pharmaceutical industry. At the 26th Pharmatech & ingredients 2025 exhibition in Russia, Shanghai JSD New Medical Material Co., Ltd showcased its focus and breakthroughs in infusion packaging components, presenting a technology demonstration on “safety assurance” to the Eastern European and Central Asian markets. The company focuses on improving the reliability of its overall blow-fill-seal (BFS) technology solutions, with its core exhibit—a new generation of integrated co-injection cap—serving as a key bridge connecting advanced production processes and final medication safety.
At the exhibition, Shanghai JSD New Medical Material Co., Ltd went beyond simply displaying individual products, creating a miniature ecosystem showcasing everything from “materials science” to “end-use applications.” BFS (Blow-Fill-Seal) technology, due to its superior sterility, has become the mainstream packaging method for high-end infusion products. However, the integrity of the technology depends on the precise coordination of every step. JSD’s technical experts pointed out that the bottle cap, as the final line of defense in sealing, directly determines the stability of the drug throughout its distribution, storage, and clinical use through its material structure and functional design. The co-injection caps showcased by the company achieve an optimal balance of mechanical properties, barrier properties, and biosafety through unique molecular structure design and molding processes, providing customized solutions, especially for sensitive formulations such as protein drugs and intravenous nutrition solutions.
During the exchange, the technical director of a large Russian pharmaceutical company stated that with increased investment in biosimilars in the region, the demand for high-barrier, low-absorption packaging is becoming increasingly urgent. Shanghai JSD provides not only a product, but also a set of validated compatibility testing data and technical support solutions, which helps them accelerate the evaluation process for new product development. Many attendees expressed high appreciation for JSD’s ability to provide packaging documentation that complies with ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) guidelines on stability.
This participation in the exhibition marks Shanghai JSD’s deepening role from a “product supplier” to a “technology partner.” The company’s head of international business emphasized, “The Eurasian market is currently undergoing a period of rapid upgrading of pharmaceutical quality standards. We have observed that our customers’ core pain points have shifted from acquiring components to seeking systematic support that can enhance their product competitiveness and compliance efficiency. Our co-capping technology is precisely the entry point to embed ourselves into our customers’ value chain and jointly address regulatory and market challenges.”
Through this Pharmatech & Ingredients exhibition, Shanghai JSD New Medical Material Co., Ltd not only garnered potential order intentions but also gained a deeper understanding of specific regulatory trends in regional markets and clients’ R&D pipelines. The company plans to use this as a foundation to establish localized technical service centers, enabling more agile responses to customer needs, collaborating with pharmaceutical companies across Eurasia to provide safer and more effective drug packaging for patients worldwide, and jointly shaping the future of the pharmaceutical industry.
